Our mission
CURAXON Ltd. is a biopharmaceutical company focused on developing innovative therapies for patients with diseases of the central nervous system, who have high medical needs and limited treatment options.
Our goal is to develop compounds with new pharmacokinetic and pharmacodynamic properties that exhibit high therapeutic
efficacy. Our preferred approach involves modifying existing compounds to fundamentally alter their pharmacological
properties, increase pharmacological efficacy, and leverage new modes of action.
The name "Curaxon" is derived from "cur(e)-axon" and inspired by "corazon/coracao," the Spanish/Portuguese words for
"heart." This name represents our commitment to carry out our work with dedication, focus, and heart.
Founded in 2020, CURAXON Ltd. is headquartered in Oetwil an der Limmat, near Zurich, Switzerland.
We are committed to delivering innovative treatments to improve the quality of life for patients with neurodegenerative CNS disorders. Our team has built a balanced and robust pipeline comprised of drug candidates and has a proven track record of drug development and commercialization.
Stefan Armin Kolb is an accomplished medical scientist with many years of experience in cell research
and global management of specialty care products in neurometabolic diseases. He graduated from the University of
Zurich with a degree in medicine and completed a post-graduate course in experimental medicine.
After graduation, he began his professional career at the University of Zurich, where he held various positions
in the anatomical department and the neuroimmunological division of the clinical immunology department. He also
served as the head of the diagnostic electron microscopy laboratory, where he conducted ultrastructural tissue
analysis of rare metabolic diseases, including lysosomal storage disorders.
Since 2001, he has worked in leading positions in the pharmaceutical industry, gaining particular expertise in
neurology, psychiatry, and endocrine care, with a focus on Alzheimer’s disease, schizophrenia, and rare neurodegenerative
lysosomal storage disorders. For over 10 years, he led the Global MedAffairs team for specialty care products at Actelion.
Stefan Kolb is the lead or co-author of more than 40 publications in the fields of neuroimmunology, lysosomal storage diseases, and, more
recently, diagnostic indices and algorithms.
CURAXON ltd
Rütistrasse 12
8955 Oetwil an der Limmat
[email protected]
+41 79 558 12 29